{"id":79328,"date":"2026-04-29T18:39:15","date_gmt":"2026-04-29T13:09:15","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=79328"},"modified":"2026-04-29T18:39:17","modified_gmt":"2026-04-29T13:09:17","slug":"piramal-pharma-q4-fy26-results","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-fy26-results\/","title":{"rendered":"Piramal Pharma Q4 FY26 Results Consolidated Loss Rs 8.82 Crore Impairment Charge Rs 176 Crore"},"content":{"rendered":"<div class=\"meta-block\">\n<p><span style=\"font-size: revert; color: initial;\">Piramal Pharma announced its Q4 FY26 financial results on April 28, 2026, posting a Net Loss of Rs 8.82 crore lower year-on-year, as the Pharmaceuticals and CDMO company delivered its January to March 2026 quarter earnings. Investors seeking live stock data, expert analysis, and research on <\/span><strong style=\"font-size: revert; color: initial;\">Piramal Pharma Q4 FY26 results<\/strong><span style=\"font-size: revert; color: initial;\"> can track the stock at <\/span><a style=\"font-size: revert;\" href=\"https:\/\/univest.in\/stocks\/PPLPHARMA\"><strong>Piramal Pharma on Univest<\/strong><\/a><span style=\"font-size: revert; color: initial;\">.<\/span><\/p>\n<\/div>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-fy26-results\/#Piramal_Pharma_Q4_FY26_Financial_Highlights\" title=\"Piramal Pharma Q4 FY26 Financial Highlights\">Piramal Pharma Q4 FY26 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-fy26-results\/#Piramal_Pharma_Q4_FY26_Performance_Analysis\" title=\"Piramal Pharma Q4 FY26 Performance Analysis\">Piramal Pharma Q4 FY26 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-fy26-results\/#Full_Year_FY26_Business_Summary\" title=\"Full Year FY26 Business Summary\">Full Year FY26 Business Summary<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-fy26-results\/#Management_Outlook_and_FY27_Priorities\" title=\"Management Outlook and FY27 Priorities\">Management Outlook and FY27 Priorities<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-fy26-results\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-fy26-results\/#Frequently_Asked_Questions_FAQs\" title=\"Frequently Asked Questions FAQs\">Frequently Asked Questions FAQs<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-fy26-results\/#What_was_Piramal_Pharma_Q4_FY26_PAT\" title=\"What was Piramal Pharma Q4 FY26 PAT?\">What was Piramal Pharma Q4 FY26 PAT?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-fy26-results\/#What_was_Piramal_Pharma_revenue_in_Q4_FY26\" title=\"What was Piramal Pharma revenue in Q4 FY26?\">What was Piramal Pharma revenue in Q4 FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-fy26-results\/#Did_Piramal_Pharma_declare_a_dividend_for_FY26\" title=\"Did Piramal Pharma declare a dividend for FY26?\">Did Piramal Pharma declare a dividend for FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-fy26-results\/#How_did_Piramal_Pharma_perform_in_FY26_overall\" title=\"How did Piramal Pharma perform in FY26 overall?\">How did Piramal Pharma perform in FY26 overall?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-fy26-results\/#What_is_the_outlook_for_Piramal_Pharma_in_FY27\" title=\"What is the outlook for Piramal Pharma in FY27?\">What is the outlook for Piramal Pharma in FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-fy26-results\/#Where_can_I_track_Piramal_Pharma_stock_and_results\" title=\"Where can I track Piramal Pharma stock and results?\">Where can I track Piramal Pharma stock and results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-fy26-results\/#What_sector_does_Piramal_Pharma_operate_in\" title=\"What sector does Piramal Pharma operate in?\">What sector does Piramal Pharma operate in?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-fy26-results\/#Is_Piramal_Pharma_a_good_investment_after_Q4_FY26_results\" title=\"Is Piramal Pharma a good investment after Q4 FY26 results?\">Is Piramal Pharma a good investment after Q4 FY26 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-q4-fy26-results\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Piramal_Pharma_Q4_FY26_Financial_Highlights\"><\/span><strong>Piramal Pharma Q4 FY26 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Piramal Pharma reported a Q4 FY26 consolidated loss of Rs 8.82 crore, primarily due to a one-time impairment charge of Rs 176 crore on intangible assets under development. The impairment followed a reassessment of market conditions and updated commercial viability estimates for certain R and D assets. Excluding the impairment, underlying business operations showed improving trends.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Metric<\/th>\n<th>Q4 FY26<\/th>\n<th>Q4 FY25<\/th>\n<th>Change<\/th>\n<\/tr>\n<tr>\n<td>Revenue \/ Total Income<\/td>\n<td>approximately Rs 1,200 crore<\/td>\n<td>Refer NSE filing<\/td>\n<td>Grew (year-on-year growth)<\/td>\n<\/tr>\n<tr>\n<td>Net Loss<\/td>\n<td>Rs 8.82 crore<\/td>\n<td>Refer NSE filing<\/td>\n<td>Lower YoY<\/td>\n<\/tr>\n<tr>\n<td>Full Year FY26 PAT<\/td>\n<td>Refer annual filing<\/td>\n<td>Refer filing<\/td>\n<td>As reported<\/td>\n<\/tr>\n<tr>\n<td>Dividend<\/td>\n<td>Not declared<\/td>\n<td>Refer filing<\/td>\n<td>FY26 final<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Piramal_Pharma_Q4_FY26_Performance_Analysis\"><\/span><strong>Piramal Pharma Q4 FY26 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Piramal Pharma&#8217;s CDMO (Contract Development and Manufacturing Organisation) business saw improving RFP momentum in H2 FY26, driven by meaningful recovery in US biopharma funding (up 75 percent YoY in H2 FY26) and increased M and A activity driving outsourcing demand.<\/p>\n<p>The Consumer Healthcare business of Piramal Pharma showed growth momentum with Power Brands leading recovery. The company also completed the Kenalog acquisition and scaled inhalation anesthesia sales in ex-US markets, setting up FY27 growth.<\/p>\n<p><em>Also Read:\u00a0<a href=\"https:\/\/univest.in\/blogs-2\/how-to-invest-via-univest\/\">How to Invest Via Univest<\/a><\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Full_Year_FY26_Business_Summary\"><\/span><strong>Full Year FY26 Business Summary<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>FY26 was described by management as a transitional year for Piramal Pharma, shaped by external disruptions including inventory destocking, slower H1 CDMO order inflows, and softer inhalation anesthesia traction. The company exited FY26 on a stronger note with improving momentum.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Management_Outlook_and_FY27_Priorities\"><\/span><strong>Management Outlook and FY27 Priorities<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Piramal Pharma&#8217;s FY27 outlook is constructive. Capex of USD 94 million invested in FY26 to scale sterile injectable and payload-linker capacities at Lexington and Riverview sites positions the CDMO business for meaningful revenue pick-up in FY27.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Piramal Pharma Q4 FY26 results<\/strong> reflect the company&#8217;s operational performance in the January to March 2026 quarter with Net Loss of Rs 8.82 crore. The Pharmaceuticals and CDMO company&#8217;s results are an important input for investors tracking the earnings season. Investors should review the full exchange filing on NSE and BSE for complete audited financials before making any investment decisions.<\/p>\n<p><em>This article is for informational and educational purposes only. It is not investment advice. Please consult a SEBI registered investment advisor before making any investment decisions. Past performance is not indicative of future results.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_FAQs\"><\/span><strong>Frequently Asked Questions FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Piramal_Pharma_Q4_FY26_PAT\"><\/span><strong>What was Piramal Pharma Q4 FY26 PAT?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Piramal Pharma reported Q4 FY26 Net Loss of Rs 8.82 crore, lower year-on-year. The results were announced on April 28, 2026 via exchange filings on NSE and BSE.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Piramal_Pharma_revenue_in_Q4_FY26\"><\/span><strong>What was Piramal Pharma revenue in Q4 FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Piramal Pharma reported Q4 FY26 revenue of approximately Rs 1,200 crore (year-on-year growth). Investors should refer to the complete NSE and BSE exchange filing for the audited revenue breakdown.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_Piramal_Pharma_declare_a_dividend_for_FY26\"><\/span><strong>Did Piramal Pharma declare a dividend for FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>As per available information, Piramal Pharma has not declared a dividend for FY26 in the Q4 results announcement. Refer to the official exchange filing for the latest update.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_did_Piramal_Pharma_perform_in_FY26_overall\"><\/span><strong>How did Piramal Pharma perform in FY26 overall?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>FY26 was described by management as a transitional year for Piramal Pharma, shaped by external disruptions including inventory destocking, slower H1 CDMO order inflows, and softer inhalation anesthesia traction. The company exited FY26 on a stronger note with improving momentum&#8230;. Investors can track the complete annual performance metrics in the company&#8217;s FY26 annual report and exchange filings.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_outlook_for_Piramal_Pharma_in_FY27\"><\/span><strong>What is the outlook for Piramal Pharma in FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Piramal Pharma&#8217;s FY27 outlook is constructive. Capex of USD 94 million invested in FY26 to scale sterile injectable and payload-linker capacities at Lexington and Riverview sites positions the CDMO business for meaningful revenue pick-up in FY27.. For real-time updates on the stock, investors should monitor regulatory filings and analyst commentary.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_track_Piramal_Pharma_stock_and_results\"><\/span><strong>Where can I track Piramal Pharma stock and results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Investors can track Piramal Pharma (NSE: PPLPHARMA) share price, financial results, and analyst data on NSE India, BSE India, and financial platforms. The Q4 FY26 results were filed on April 28, 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_sector_does_Piramal_Pharma_operate_in\"><\/span><strong>What sector does Piramal Pharma operate in?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Piramal Pharma operates in the Pharmaceuticals and CDMO sector in India. The company is listed on both NSE and BSE. Investors should review the company&#8217;s business model, competitive positioning, and risk factors before making any investment decision.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Piramal_Pharma_a_good_investment_after_Q4_FY26_results\"><\/span><strong>Is Piramal Pharma a good investment after Q4 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Whether Piramal Pharma is a good investment depends on your individual financial goals, risk tolerance, and investment horizon. The Q4 FY26 results provide one data point about the company&#8217;s performance. Please consult a SEBI registered financial advisor before making any investment decision.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/vrl-logistics-q4-results-2026-2\">VRL Logistics Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/vraj-iron-and-steel-q4-results-2026\">Vraj Iron and Steel Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/voltas-q4-results-2026\">Voltas Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/voltamp-transformers-q4-results-2026\">Voltamp Transformers Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/vodafone-idea-q4-results-2026\">Vodafone Idea Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Piramal Pharma Q4 FY26 results: Net Loss Rs 8.82 crore, lower YoY. Key highlights, financial analysis, outlook and FAQs. April 2026.<\/p>\n","protected":false},"author":29,"featured_media":79787,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[4027],"class_list":["post-79328","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-q4-fy26-results"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1777468180:23"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["75"],"rank_math_title":["Piramal Pharma Q4 FY26 Results Consolidated Loss Rs 8.82 Crore Impairment Charge Rs 176 Crore"],"rank_math_description":["Piramal Pharma Q4 FY26 results: Net Loss Rs 8.82 crore lower year-on-year, Key highlights, financial table, outlook and FAQs. April 2026."],"rank_math_focus_keyword":["Piramal Pharma Q4"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["79787"],"_edit_last":["23"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["9741"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/29183839\/Piramal-Pharma-Q4-FY26-Results.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/79328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=79328"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/79328\/revisions"}],"predecessor-version":[{"id":79788,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/79328\/revisions\/79788"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/79787"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=79328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=79328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=79328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}